Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Annovis Bio (ANVS)
NYSE:ANVS
Annovis Bio (ANVS) Stock Price & Analysis
405 Followers
ANVS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.86 - $22.49
Previous Close$5.18
Volume609.60K
Average Volume (3M)445.00K
Market Cap
$57.04M
Enterprise Value$50.68M
Total Cash (Recent Filing)$6.35M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-0.8
Beta1.21
Next Earnings
May 09, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.22
Shares Outstanding11,011,299
10 Day Avg. Volume1,655,729
30 Day Avg. Volume445,000
Standard Deviation0.40
R-Squared0.06
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)9.01
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.36
Forecast
1Y Price Target
$22.75Price Target Upside339.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
Annovis Bio News
PremiumCompany Announcements
Annovis Bio CFO Henry Hagopian Resigns, CEO Steps In
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsBuntanetap treatment groups showed statistically significant improvement from their corresponding baseline, highlighting the drug's potential effectiveness in treating Alzheimer's disease.
Financial OutlookAnalyst reiterates Buy rating, indicating a positive outlook on the stock, with a 12-month target of $30 based on the expected positive trial results and strong financial positioning.
Safety ProfileBuntanetap was very well-tolerated with most reported adverse events being mild-to-moderate in severity, underscoring its favorable safety profile.
Bears Say
Clinical Trial ResultsThe subgroup with early AD showed a statistically significant improvement, but the results are based on very small sample sizes, raising concerns about the reliability of the data.
Financial PerformanceAnnovis Bio recorded a full-year net loss significantly wider than anticipated, with projections indicating the net loss may continue to increase.
Funding ConcernsThe company faces a potential cash shortfall, requiring an estimated $350 million to reach cash flow positivity, while current reserves are markedly insufficient.
---
Ownership Overview
26.94% Insiders
4.00% Mutual Funds
3.61% Other Institutional Investors
65.45% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ANVS FAQ
What was Annovis Bio’s price range in the past 12 months?
Annovis Bio lowest stock price was $4.86 and its highest was $22.49 in the past 12 months.
What is Annovis Bio’s market cap?
Currently, no data Available
When is Annovis Bio’s upcoming earnings report date?
Annovis Bio’s upcoming earnings report date is May 09, 2024 which is in 5 days.
How were Annovis Bio’s earnings last quarter?
Annovis Bio released its earnings results on Apr 02, 2024. The company reported -$2.25 earnings per share for the quarter, missing the consensus estimate of -$0.834 by -$1.416.
Is Annovis Bio overvalued?
According to Wall Street analysts Annovis Bio’s price is currently Undervalued.
Does Annovis Bio pay dividends?
Annovis Bio does not currently pay dividends.
What is Annovis Bio’s EPS estimate?
Annovis Bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Annovis Bio have?
Annovis Bio has 11,011,299 shares outstanding.
What happened to Annovis Bio’s price movement after its last earnings report?
Annovis Bio reported an EPS of -$2.25 in its last earnings report, missing expectations of -$0.834. Following the earnings report the stock price went down -6.522%.
Which hedge fund is a major shareholder of Annovis Bio?
Currently, no hedge funds are holding shares in ANVS
---
Annovis Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$22.75 (339.19% Upside)
$22.75 (339.19% Upside)
Blogger Sentiment
Bullish
ANVS Sentiment 87%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Positive
Last 7 Days >0.1%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.66%
12-Months-Change
Fundamentals
Return on Equity
-546.40%
Trailing 12-Months
Asset Growth
-71.66%
Trailing 12-Months
Company Description
Annovis Bio
Annovis Bio Inc is a United States based clinical stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neuro degenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301.
---
ANVS Stock 12 Months Forecast
Average Price Target
$22.75
▲(339.19% Upside)
Technical Analysis
Best Analysts Covering ANVS
1 Year
1 Year Success Rate
0/14 ratings generated profit
1 Year Average Return
-43.53%
reiterated a buy rating 5 days ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -43.53% per trade.
---